Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
The Senior Director, Regulatory Affairs CMC, reporting to the Chief Regulatory officer, is responsible for leading the development and execution of global CMC regulatory strategies and content plans across the Tango portfolio, ensuring alignment with scientific principles and risk-based approaches. This role drives the planning, preparation, and delivery of high-quality CMC regulatory submissions, partners cross-functionally with technical and program teams, and provides strategic guidance to support efficient development and successful regulatory outcomes across all stages of the product lifecycle.
Key responsibilities include:
- Develop and execute global CMC regulatory strategy for all Tango products. Refine regulatory strategy as new data become available and re-assess as necessary. Assess regulatory risks and develop mitigations plan, when applicable.
- Develop and get buy-in on regulatory CMC strategy for Health Authority (HA) responses as needed.
- Ensure the CMC development strategy meets global regulatory requirements for registration and over the lifecycle of the product.
- Drive and be accountable for the preparation of dossiers for submission to Health Authorities (NDA/MAA/IND/CTA and post approval changes). Work with the CMC team to develop CMC content and submission plans. Develop strategy for providing responses to HA questions (ensure alignment with CMC functions and global strategy).
- Provide accurate regulatory assessments of chemistry, manufacturing and controls changes to teams/projects and execute regulatory planning and implementation.
- Effectively and tactfully communicate with HA; maintain good rapport and credibility with HA.
- In collaboration with Regulatory Leader, as applicable, determine timing and strategy for HA meetings, prepare company staff for interactions, lead CMC meetings with Health Authorities. Ability to negotiate with HA personnel.
- Provide CMC Regulatory support to health authority inspections.
What You Bring:
- Advanced degree with 12+ years of experience developing small molecule, CMC regulatory strategies, with deep expertise in product development and its application to global regulatory strategy; recognized as a subject matter expert in CMC development
- Experience leading interactions with Health Authorities
- Experienced leader with a demonstrated track record of driving results and achieving success
- Strong knowledge of global HA laws, regulations, guidance, and global regulation submission pertaining to small molecule CMC development and registration topics
- Strong understanding of biology, chemistry and/or engineering relevant to pharmaceutical industry
- Experience in communicating cross-functionally. Presents and defends CMC regulatory strategy and opinion to project teams; recognizes global regulatory impact
- Hands on experience in submitting multiple NDAs / MAAs for a new chemical entity and managing the registration process and life cycle management
- Highly organized, detail-oriented, and solution-focused, with the ability to manage multiple priorities and drive execution to completion
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
#LI-Hybrid
Skills Required
- Advanced degree in a relevant field
- 12+ years of experience in CMC regulatory strategies
- Experience leading interactions with Health Authorities
- Strong knowledge of global regulations and guidance
- Hands-on experience in NDA/MAA submissions
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
